A main player in the pharmaceutical sector, Natco Pharma is renowned for both its specialty and generic drugs. Following poor quarterly results, the company's stock price has come under scrutiny recently. Due to investor concerns about Natco Pharma's financial performance, the company's shares fell by nearly 19% on February 13, 2025.
This article gives potential investors a complete insight into Natco Pharma by exploring its current market capitalization, price-to-earnings (PE) ratio and analyst recommendations.
Read more: SAIL Share Price
Overview of Natco Pharma's Financial Performance
Natco Pharma reported a net profit of Rs 1,324 crore in Q3 FY25, down 37.7% from Rs 2,127 crore in the same quarter last year. Moreover, the company's total sales declined 18.1% to Rs 6,511 crore from Rs 7,956 crore last year. As a result of this decline, investors are now more concerned about the company's profitability and growth trajectory.
Market Capitalization
The recent decline in share prices has led to a significant decline in Natco Pharma's market capitalisation as of February 13, 2025. After opening at ₹1,039.1, the stock fell sharply to an intraday low of ₹992.15 and then to ₹1,004 per share. This decline has increased the general market hesitancy about the company's prospects. Investors' confidence about Natco's ability to bounce back and expand in a competitive environment is reflected in the company's current market capitalisation as well as its immediate financial results.
Price-to-Earnings (PE) Ratio
The recent decline in share prices has led to a significant decline in Natco Pharma's market capitalisation as of February 13, 2025. After opening at ₹1,039.1, the stock fell sharply to an intraday low of ₹992.15 and then to ₹1,004 per share. This decline has added to the general market hesitation about the company's prospects. Investors' confidence in Natco's ability to bounce back and expand in a competitive environment is reflected in the company's current market capitalization in addition to its immediate financial results.
Analyst Recommendations
Investor decisions are heavily influenced by analysts' recommendations. Many experts have revised their forecasts for Natco Pharma in light of the poor third quarter results. Amid concerns over continued profitability and market competitiveness, some analysts have adopted "sell" recommendations, while others have retained "hold" recommendations based on the company's long-term prospects and the recent announcement of a dividend of ₹1.50 per share.
Keep following 5 Dariya News for more news and articles.